Melior Discovery Information

Melior Discovery is a preclinical in vivo pharmacology contract research organization (CRO) headquartered in Exton, Pennsylvania. Founded in 2005, Melior specializes in in vivo phenotypic screening, drug repositioning (repurposing), and efficacy evaluation for global pharmaceutical and biotechnology companies. At the core of our capabilities is theraTRACE®, a proprietary high-throughput phenotypic screening platform utilizing multiplexed in vivo disease models. This unique platform allows drug discovery teams and developers to evaluate compounds across up to 40 distinct animal models of human disease simultaneously, spanning 14 therapeutic areas to uncover unexpected indications and de-risk pipeline decisions. Core Preclinical Services & Platforms: theraTRACE®: Multiplexed phenotypic screening for indications discovery. immuno-theraTRACE™: Oncology-focused screening for immune-modulating agents and tumor models. opioidTRACE®: Analgesic-focused platform evaluating pain pathways and abuse liability. Custom In Vivo Models: Over 150 validated rat and mouse models covering CNS, metabolic, inflammation, dermatology, and GI disorders. Supporting Services: Pharmacokinetic (PK) evaluations, bioanalytical services, and specialized surgery/implants (e.g., orthotopic intracranial). Since 2005, Melior has served hundreds of biopharma partners, from venture-backed startups to multinational pharmaceutical firms. Melior was recognized as CRO of the Year by Life Sciences Review and named a Top 20 CRO by Pharma Tech Outlook.